MBrace Therapeutics

We are excited to share that Reena R Desai has joined MBrace as #ChiefLegalOfficer and Corporate Secretary. Reena brings almost 25 years of experience from various #biotech and #pharmaceutical companies. She will be responsible for shaping the company’s #legal strategy at MBrace. Welcome, Reena! 

It’s an exciting time in the field of #oncology and #ADC innovation. It was impactful for our team to be a part of a community of dedicated and passionate individuals at #ASCO24, and we look forward to continuing to explore MBRC-101's therapeutic potential to meaningfully impact outcomes for individuals with difficult-to-treat cancers.

We look forward to presenting a trial in progress update for the Phase 1/1b study of MBRC-101 at #ASCO24. This clinical program demonstrates our commitment to both break new ground in #ADC innovation and bridge gaps within current #cancer treatment paradigms. Learn more: https://bit.ly/4bD5Fos

The Wall Street Journal recently featured MBrace along with other leading innovators in the #ADC field, highlighting our SPARTA platform’s ability to search for potential novel targets that allow #ADCs to zero in on #tumors, exit the bloodstream and enter #cancer cells: https://bit.ly/3y3KkFF

We were honored to present and participate in #AACR24. The strength of scientific progress and incredible resolve to meaningfully advance the treatment of #cancer has never been more apparent. We are inspired by the connections we made with fellow innovators, advocates, survivors and patients.

#ICYMI: STAT recently covered the appointment of MBrace chief scientific officer Steve Alley, Ph.D., and offered a glimpse into his unique interests and hobbies outside of the lab, including hiking and bird watching. Read more about Steve’s favorite hiking and bird watching experiences, including a chance encounter with a Magellanic penguin, here: https://lnkd.in/ei53g6J5

Our Director of Research & Development, Fernanda Staquicini, Ph.D., will be presenting at #AACR24 on Sunday, April 7. We’re excited to connect with industry peers to showcase the strides MBrace is making in the #oncology space, specifically around our investigational #ADC, MBRC-101. Learn more: https://lnkd.in/ekq5E7Pz

Please join us in welcoming the newest addition to our #leadership team, Steve Alley, Ph.D., joining as chief scientific officer! With over 20 years of experience in discovery and #drugdevelopment, from leading clinical development programs and overseeing a robust commercial portfolio of #antibodydrugconjugates, Dr. Alley will play a pivotal role in driving our #research and development efforts forward. #oncologynews #biotech #stem #oncology https://lnkd.in/e3wqf7g8

It is an honor to be recognized by BioPharma Reporter as one of the top #ADC startups favored by venture capital #investors in 2023. Read the full article to discover how we’re making strides in the #oncology space following our our $85 million Series B financing led by TPG: https://lnkd.in/efTvW7xV #cancer #biotech #innovation #science #stem 

Today we announced the successful initiation of patient dosing in our Phase 1 #clinicaltrial evaluating our investigational #ADC, MBRC-101. The study will assess the safety and anti-tumor activity of MBRC-101 in patients with advanced metastatic #solidtumors refractory to standard treatment. Learn more: https://lnkd.in/edWEVrza #oncologynews #stem #innovation #clinicaltrials